An American study revealed that exhausted TCF1+Tim-3− CD8+ tumor-infiltrating lymphocytes (TILs) not exhausted TCF1−Tim-3+ CD8+ TILs can respond to anti-PD-1 therapy and may be an effective predictor of immunotherapy in melanoma patients [18]. This evidence concerns the gene CD8A and neoplasm.